Abstract
The rescheduling of cannabis, from the US Drug Enforcement Administration (DEA), current most restrictive (Schedule 1) designation, would be an important step for cannabis research and researchers. We are researchers who have experience with cannabis research in pre-clinical, clinical, and policy domains, who represent a range of social science disciplines (e.g., Psychology, History). In this commentary, we share our perspectives on the history, policies, challenges and benefits of moving cannabis from the current Schedule 1 designation (similar to heroin) to the less restrictive Schedule III (similar to ketamine). The rescheduling has the potential to contribute in multiple ways to research on cannabis' effects on the brain and behavior, policies for regulating medicinal and recreational use, and the use of cannabis to treat health conditions such as chronic pain. While there is scientific evidence to support this rescheduling, there also are challenges and pushback for keeping the regulations as they currently exist. Although "the devil is in the details," we present our reasons to advocate for improving access to cannabis for research.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
